The age- and sex-matched multivariate analysis showed that SGLT2 inhibitor therapy significantly reduced the risk of total cardiac arrhythmia (HR: 0.58, 95% CI: 0.38–0.89, p = 0.013). This evidence concerns the gene SLC5A2 and cardiac arrhythmia.